SciELO - Scientific Electronic Library Online

 
vol.29 número1La objeción de conciencia y la interrupción voluntaria del embarazo: ¿Cómo conciliar su ejercicio con los derechos de las usuarias? índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Links relacionados

Compartir


Revista Médica del Uruguay

versión On-line ISSN 1688-0390

Resumen

PAPA, Mercedes Patricia. Uso del metilfenidato en pacientes con cáncer avanzado. Rev. Méd. Urug. [online]. 2013, vol.29, n.1, pp.58-63. ISSN 1688-0390.

Summary Introduction: Cancer, both the disease and its treatment are associated with a series of physical and psychosocial symptoms such as fatigue, depression, drowsiness and hypoactive delirium that need to be identified and treated in order to optimize the patients' quality of life. Methylphenidate, a psychostimulant drug used for the attention deficit disorder, is used within the context of palliative medicine to control these symptoms in patients suffering from advanced cancer. Objectives: The present articles aims to explore the evidence that justifies the use of this drug in the symptomatic handling of oncological patients, as well as its efficacy and safety in this population. Method: We conducted a search in the Medline, Pubmed y Embase databases, both in English and in Spanish, from 1990 until today. Conclusions: Methylphenidate is the most widely used psychostimulant in palliative medicine. As it increases the level of brain alert it results in a potential benefit for the handling of symptoms in patients with advanced cancer, such as the cancer associated fatigue, sedation associated to the use of opioids, depression and hypoactive delirium.

Palabras clave : METHYLPHENIDATE [therapeutic use]; DEPRESSION; DELIRIUM; FATIGUE; NEOPLASMS PALLIATIVE CARE.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons